LAN QUACH: Open Payments
NPI 1730462904 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,303 in 100 payments from 12 companies in 2025. Trend: 2023 $4,599 · 2024 $3,509 · 2025 $4,303
Food & beverage: $4,188Consulting: $115
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 13 | $649 |
| Neurocrine BioSciences, Inc. | 9 | $621 |
| Janssen Pharmaceuticals, Inc | 7 | $558 |
| Otsuka America Pharmaceutical, Inc. | 9 | $491 |
| Lundbeck LLC | 19 | $460 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $386 |
| Alkermes, Inc. | 12 | $381 |
| Vanda Pharmaceuticals Inc. | 3 | $264 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $152 |
| E.R. Squibb & Sons, L.L.C. | 1 | $121 |
Products named: REXULTI, Auvelity, INGREZZA, CAPLYTA, INVEGA SUSTENNA, FANAPT, LYBALVI, SPRAVATO.
Industry payments across CA — which companies pay providers there.
